Nikko Asset Management Americas Inc. purchased a new stake in ProQR Therapeutics NV (NASDAQ:PRQR) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 289,511 shares of the biopharmaceutical company’s stock, valued at approximately $4,016,000. Nikko Asset Management Americas Inc. owned approximately 0.74% of ProQR Therapeutics as of its most recent SEC filing.
Other large investors have also recently added to or reduced their stakes in the company. Morgan Stanley lifted its position in shares of ProQR Therapeutics by 39.8% during the third quarter. Morgan Stanley now owns 406,284 shares of the biopharmaceutical company’s stock worth $7,862,000 after purchasing an additional 115,709 shares during the last quarter. Federated Investors Inc. PA bought a new position in shares of ProQR Therapeutics during the third quarter worth about $5,058,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of ProQR Therapeutics during the fourth quarter worth about $53,000. Virtus ETF Advisers LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter worth about $263,000. Finally, Lindbrook Capital LLC bought a new position in shares of ProQR Therapeutics during the fourth quarter worth about $25,000. Hedge funds and other institutional investors own 52.83% of the company’s stock.
Several equities analysts have recently commented on PRQR shares. BidaskClub raised shares of ProQR Therapeutics from a “sell” rating to a “hold” rating in a report on Friday. Zacks Investment Research cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, May 1st. ValuEngine cut shares of ProQR Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, April 13th. Finally, HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of ProQR Therapeutics in a report on Thursday, February 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $28.67.
NASDAQ PRQR traded down $0.06 during trading hours on Friday, reaching $12.27. The company’s stock had a trading volume of 194,600 shares, compared to its average volume of 222,151. The company has a quick ratio of 10.08, a current ratio of 10.08 and a debt-to-equity ratio of 0.14. ProQR Therapeutics NV has a 52 week low of $5.10 and a 52 week high of $24.00. The stock has a market capitalization of $450.15 million, a P/E ratio of -9.51 and a beta of 0.50.
ProQR Therapeutics (NASDAQ:PRQR) last issued its earnings results on Wednesday, February 27th. The biopharmaceutical company reported ($0.38) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.15. As a group, equities research analysts expect that ProQR Therapeutics NV will post -1.65 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This article was posted by Sundance Herald and is the sole property of of Sundance Herald. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://sundanceherald.com/2019/05/24/nikko-asset-management-americas-inc-invests-4-02-million-in-proqr-therapeutics-nv-prqr.html.
About ProQR Therapeutics
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
Featured Article: What are catch-up contributions?
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.